Chloroquine and hydroxychloroquine as potential therapies against COVID-19

Chloroquine and hydroxychloroquine as potential therapies against COVID-19
Author(s):
Yewange Sangmeshwar, Deshpande Renuka, Nikhil Waghmare, Vidyasagar Gali, Shyamlila B. Bavage, Nandkishor B. Bavage
Keywords:
chloroquine clinical research clinical trials corona virus in COVID-19 disease & medicine hydroxychloroquine malaria nut shell SARS-CoV-2
Abstract
The desperate search to find effective treatments for coronavirus disease 2019 (COVID-19), 2 generic drugs, used largely by rheumatologists and dermatologists to treat immune-mediated diseases, have entered the spotlight. The antimalarials hydroxychloroquine (HCQ) and chloroquine (CQ) have demonstrated antiviral activity against severe acute respiratory syndrome–coronavirus 2 (SARS–CoV-2) in vitro and in small, poorly controlled or uncontrolled clinical studies (1–3). Normally, such research would be deemed hypothesis-generating at best. Here, we try to provide guidance regarding clinical decision making both for patients with COVID-19 and those with immune-mediated conditions, such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), and strategies to mitigate further harm to these patients.
Article Details
Unique Paper ID: 149343 Publication Volume & Issue: Volume 6, Issue 12 Page(s): 15 - 19
Article Preview & Download

Share This Article

NCSEM 2024

National Conference on Sustainable Engineering and Management - 2024

Last Date: 15th March 2024

IJIRT.org enables door in research by providing high quality research articles in open access market.

Send us any query related to your research on editor@ijirt.org